Mikhail Blagosklonny: Excelling as a Scientist and an Editor

Mikhail Blagosklonny is a professor, an author, and a renowned scientist. He has worked as a research scientist on tandfonline.com before being appointed a professor of oncology at the Roswell Park Cancer Institute. He is the editor-in-chief of Cell Cycle which he also founded. He is the co-editor-in-chief of Oncoscience, Aging, and Oncotarget. Oncotarget is a peer-reviewed journal that is published weekly. It covers papers on oncology, molecular biology, and aging. His work at Oncotarget has made it become one of the top medical journals in publication at https://www.researchgate.net/profile/Mikhail_Blagosklonny. Mikhail is the Associate Editor of some journals such as Cancer Research, Cell Death and Differentiation, and the American Journal of Pathology.

Mikhail Blagosklonny’s work ranges from cancer and molecular biology to oncology and gerotargets. His work has consisted of clinical investigations to help come up with data and hypotheses. These have helped to come up with new forms of medication or to reveal information that was not previously known about the human body.

Mikhail Blagosklonny has made breakthroughs in his research on aging and what can help to cause anti-aging in recent years. His research led him to write an article on how TOR Signaling can contribute to slow aging. Mikhail Blagosklonny thinks that aging is the continual development of cells. It is purposeless when this constant development continues past the point where the cell is mature. This is why disease characterizes old age.

Blagosklonny observed that rapamycin also slowed aging. This is because cancer is an age-related disease on Impact Journals. This means that the more one ages, the higher the chances of getting cancer. Anything that works against cancer should work against aging since both come about as a result of continual cell development. Rapamycin delays cancer by delaying aging by delaying the over-development of cells. It only works if it is administered before cancer begins to form in the body. It does not function as intended if it is taken later than this. This has made him become one of the most vocal advocates of using the drug as an anti-aging agent.

The h-index is the impact factor. It applies to scholars. It is calculated by measuring the number of citations a student’s work receives and their most cited papers. The work that Blagosklonny has done over the years has resulted in him having an h-index of 83. This is evidence of how influential he has been in scientific research and his field.